We will collaborate closely with you to track your development, talk about any possible drug interactions, and modify your treatment plan as needed
Importantly, there is an absence of data demonstrating development of chronic pancreatitis in humans treated with GLP-1RAs to support this connection
Remodeling phase exhibits improved collagen organization and reduced fibrosis, resulting in stronger, more functional repaired tissue with minimal scarring
Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges
Lunch is a small teriyaki chicken bowl with rice and broccoli, 32g protein, small enough to actually finish